A case of lactic acidosis caused by stavudine in an AIDS patient by 源�以�紐� et al.
The Korean Journal of Internal Medicine: 19:66-69, 2004
INTRODUCTION
Highly active antiretroviral therapy (HAART) enhances the
immune state of immunodeficiency virus (HIV) infected patients,
by suppressing the replication of HIV. This enhancement in the
immune state reduces the risk of opportunistic infections, and
thus HAART has improved the survival and quality of life of
AIDS patients, and now plays a central role in the treatment of
HIV infection1). Nonnucleoside reverse transcriptase inhibitors
(NNRTIs), protease inhibitors (PIs) and nucleoside reverse
transcriptase inhibitors (NRTIs) are widely used for HAART1). It
has also been reported that when antiretroviral drugs, especially
NRTIs are administered, that they may cause lipodystrophy
syndrome due to the abnormal accumulation or diminution of
lipid, dyslipidemia, lactic acidosis or even an abnormal glucose
metabolism2). Lactic acidosis, in particular, is a life threatening
adverse effect, and has been associated with almost all NRTIs,
e.g., with zidovudine (AZT) or didanosine (ddI)3, 4). According to
recent reports, many cases of lactic acidosis have been
attributed to Stavudine (d4T)5-7). However, no case of lactic
acidosis has been reported in Korea. We present a case of
severe lactic acidosis caused by stavudine and include a
review of the literature.
CASE REPORT
A 44-year-old woman was admitted to the hospital because
of nausea, vomiting and paraplegia of both lower extremities.
She was diagnosed as HIV positive in June, 2000, when she
presented with retinal necrosis caused by the varicella zoster
virus. Subsequently, she was started on zidovudine, lamivudine,
and indinavir at a baseline CD4 positive T lymphocyte count of
16/µL, a CD8 positive T lymphocyte count of 86/µL and a
HIV-RNA of 1,129,768 copies/mL. Subsequently, medication
was changed to lamivudine, stavudine, lopinavir/ritonavir in April,
2002 due to leukopenia caused by the zidovudine. She
remained on this medication for 8 months, prior to December
2002, when she stopped the medication 10 days before
admission due to the symptoms mentioned above. In January
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2000, the patient was diagnosed with chronic viral hepatitis B.
She had no history of hypertension, tuberculosis or DM, and no
medication other than antiretroviral drugs had been taken. On
admission, the patient complained of general weakness,
nausea, vomiting and paralysis of both lower extremities.
However, she did not present fever, chills, abdominal pain,
constipation or diarrhea. The patient's blood pressure was
110/80 mmHg, pulse rate 80/min, respiration rate 25/min,
temperature 36℃. She had a chronically ill-looking appearance
and an alert mental status. Conjunctivae were not pale, sclerae
were not icteric and cervical lymph nodes were not palpable.
On chest auscultation, breathing sounds were clear in both
lungs; her heartbeat was regular without murmur. The Abdo-
men was soft and flat without tenderness, and bowel sounds
were normoactive. The liver and spleen were not palpable and
no palpable abdominal mass was found by physical examina-
tion. Muscle strength of both legs had decreased to GII, and
there were no deep tendon reflexes (DTRs). Neither CVA
tenderness nor pitting edema of the extremities was apparent.
A laboratory examination showed a WBC of 6,920/mm2 (neutro-
phils 58.8%, lymphocytes 29.1%, monocytes 6.9%, eosinophils
1.3%), a Hb of 14.7 mg/dL, a hematocrit of 42.3%, and a
platelet count of 159,000/mm3. Blood chemistry revealed; calcium
9.5 mg/dL, inorganic P 0.4 mg/dL, uric acid 14 mg/dL, ALP 71
IU/L, amylase 48 IU/L, lipase 111 IU/L, BUN 6.8 mg/dL,
Creatinine 0.8 mg/dL, total protein 7.0 g/dL, albumin 4.7 g/dL,
AST/ALT 71/60 IU/L, total bilirubin 2.7 mg/dL, direct bilirubin 1.7
mg/dL, Na/K/Cl/tCO2 135/3.1/95/8 mEq/L, total cholesterol 252
mg/dL, TG 305 mg/dL, HDL-cholesterol 16 mg/dL, LDL cholesterol
157 mg/dL, lactate 10.8 mmol/L (normal 0.5-1.6 mmol/L), and
creatinine kinase 3 IU/L. Immunochemistry showed positive
HBeAg, HBV DNA 1,321 pg/mL, AFP 10.61 IU/mL (normal
0-7 IU/mL), and CEA 0.566 ng/mL (normal 0-5 ng/mL). The
CD4 positive T lymphocyte count was 117/µL, the CD8 positive
lymphocyte count 687/µL, and a HIV-RNA level of 133,000
copies/mL. Her pregnancy test was negative, as were blood,
urine and stool culture. A cerebrospinal fluid examination
performed to rule out a central nervous system infection
showed no significant findings, and neither did brain MRI
(Figure 1). A contrast CT scan of the abdomen, performed to
rule out intra-abdominal malignancy, showed only a hepatic
cyst (Figure 2). Arterial blood gas analysis (ABGA) revealed a
pH of 7.291, pCO2 12.6 mmHg, pO2 142.1 mmHg, SaO2 99%,
and BE-ECF 20.6. Accordingly, a diagnosis of lactic acidosis
was made. Intravenous sodium bicarbonate infusion and
conservative treatment were immediately initiated and antire-
troviral drugs were stopped. The symptoms of nausea and
vomiting subsided on the third day of treatment and from the
tenth day, her paraplegia of both legs also started to improve.
ABGA results and lactate levels gradually normalized (Table 1)
and on the 11th day, ABGA showed pH 7.474, pCO2 39.9
mmHg, pO2 79 mmHg, SaO2 96.3%, BE-ECF +5.8, and lactate
2.9 mmol/L. The patient was discharged on the 14th day without
any signs of lactic acidosis. At the time of discharge, total
bilirubin had decreased to 1.3 mg/dL. After discharge,
antiretroviral medications were resumed in the order:- of
Figure 1. Brain MRI, showing no abnormal signal intensity or
abnormal mass lesion in T2WI. The ventricular system was
within normal limits.
Figure 2. Abdominal-pelvic CT showing small cysts in the liver.
No grossly visible mass or lymphadenopathy was present.
Table 1. Serial arterial blood gas analyses and lactate concentrations
after sodium bicarbonate infusion and discontinuation of
stavudine
Hospital day 1 day 2 day 5 day 11 day
pH
pCO2 (mmHg)
BE-ECF
Lactate (mmol/ℓ)
7.29
12.6
-20.6
10.8
7.432
18.4
-12.1
6.0
7.351
36.4
-5.5
3.7
7.474
39.9
+5.8
2.9
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lamivudine, efavirenz, and lopinavir/ritonavir; none of the
previous symptoms recurred. Two months after discharge, her
serum lactate level was 4.8 mmol/L. The patient is still on
antiretroviral therapy and is being followed up on an outpatient
basis.
DISCUSSION
HAART serves a major role in the treatment of HIV infection.
Therapy is considered if the patient is symptomatic or when
the CD4 positive T lymphocyte <350/µL or HIV-RNA >
exceeds 55,000 copies/mL in non-symptomatic patients1). For
initial therapy, two NRTIs are usually used in combination with
PIs or NNRTIs1). NRTIs suppress HIV reverse transcriptase,
which, inhibits viral DNA synthesis. However, these drugs
induce severe complications by also suppressing DNA syn-
thesis by mitochorial polymerase-γ 2). Zidovudine, the first NRTI
used in HIV treatment, can cause hepatic steatosis, lactic
acidosis and even myopathy3). Didanosine is also reported to
cause adverse effects, such as acute pancreatitis, in addition to
those caused by zidovudine5, 6). Stavudine, a derivative of thymi-
dine, which was the fourth NRTI to be used in this case, may
cause peripheral neuropathy5, 6), lactic acidosis7), cardiomyopa-
thy8), pancreatitis1) and Guillain-Barre syndrome5). These com-
plications occur due to the depletion of mitochondrial DNA
caused by the suppression of DNA polymerase-γ , followed by
dysfunction of cellular oxidative phosphorylation9). In contrast,
NNRTIs and PIs have not been reported to cause such
adverse effects of mitochondrial toxicity, which is attributed to
their selectivity for HIV reverse transcriptase1). The most com-
mon complication of NNRTIs is skin eruption, other include PIs,
hyperglycemia and dyslipidemia1, 2). Lactate is the final product
of glycolysis, which in a normal state does not accumulate in
the body. However, under circumstances such as oxygen
deprivation of tissue or impaired oxidative phosphorylation,
hyperlactatemia occurs. Lactic acidosis is defined as a serum
lactate level >5 mmol/L accompanied by metabolic acidosis10).
Since 1991, when acute hepatic failure and lactic acidosis was
first reported to be caused by didanosine11), lactic acidosis by
NRTIs has been was considered as a rare, but fatal
complication. The Ssymptoms of lactic acidosis are typically
nonspecific, but include fatigue, abdominal pain, vomiting, and
weight loss. When such symptoms are accompanied by
dyspnea on exertion, it is mandatory that serum lactate levels
be measured. The presence of tachycardia at a normal body
temperature is highly suggestive of lactic acidosis12). Since most
HIV infected patients are admitted to hospital with such nons-
pecific symptoms, it is easy to neglect lactic acidosis. Although
earlier reports have been issued on lactic acidosis due to
zidovudine or didanosine3, 4), stavudine is frequently the more
recent reported cause5-7). Since cases of fatal lactic acidosis
caused by stavudine and didanosine in pregnant women have
been reported, the administration of these drugs during preg-
nancy is now considered with a high degree of caution19, 20).
Luzzati et al.20) postulated a high possibility of mitochondrial
toxicity due to NRTIs in pregnant women, because the riboflavin
concentration runs low during pregnancy. Risk factors of lactic
acidosis, other than pregnancy, include female sex, obesity and
the duration of NRTI therapy1). Moreover, it is important that
lactic acidosis be distinguished from asymptomatic hyperlacta-
temia. John et al.13) reported that the majority of HIV-positive
patients taking NRTIs developed chronic asymptomatic hyper-
lactatemia; their average serum lactate concentration was repor-
ted to be 1.5∼3.5 mmol/L. The administration of and the dura-
tion of exposure to stavudine are reported to be major risk fac-
tors of hyperlactatemia13) and PIs or NNRTIs were not found to
meaningfully affect the development of hyperlactatemia. Howe-
ver, a minority of hyperlactatemia patients eventually developed
lactic acidosis. According to Boubaker et al.14) a significantly
higher incidence of hyperlactatemia was observed in a group of
patients treated with stavudine, and no apparent relationship
was found between age, gender, CD4 positive T lymphocyte
count and the development of hyperlactatemia. Furthermore,
in many cases, lipodystrophy, dyslipidemia, and hyperglycemia
were accompanied with hyperlactatemia. According to the report
of Yann et al.12), the annual incidences of hyperlactatemia
were 0.8% and 1.2% in NRTIs or stavudine administered AIDS
patient groups, respectively. Coghlan et al.16) reported in their
retrospective study of HIV positive patients with lactic acidosis
that the majority of patients took stavudine and didanosine.
Lactic acidosis is accompanied by myopathy, lipodystrophy,
fulminant hepatic failure, and pancreatitis in many cases1, 2).
And, stavudine is reported to cause Guillain-Barre syndrome5),
demonstrating that NRTIs damage multiple organs by deple-
ting mitochondrial DNA. Treatments for lactic acidosis include;
the immediate discontinuation of medication, conservative treat-
ment and the correction of the acidosis. Dalton et al.17) and
Yann et al.18) reported upon the successful treatment of lactic
acidosis with riboflavin and L-carnitine, but the effect of this
treatment is as unproven. The discontinuation of medication
corrects most cases of hyperlactatemia, but the continuation of
hyperlactatemia for 176 days has been reported2, 15). Because our
patient had no other causes of lactic acidosis (infection, shock,
malignancy, ischemia or cirrhosis) and did not take any medi-
cation other than the anti-retroviral drugs, the lactic acidosis
was ascribed to the NRTI. Considering that her lactic acidosis
developed while she had been taking stavudine, and that the
lactic acidosis did not recur while stavudine alone was replaced
by efavirenz, a NNRTIs, stavudine appears to have been the
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culprit. Since the total bilirubin level of the patient upon presen-
tation was elevated to twice the normal value, it was likely that
she had hepatic steatosis. After conservative treatment, how-
ever, the bilirubin level recovered to the norm, and so a liver
biopsy was not performed. Therefore, we could not entirely
exclude the possibility of hepatotoxicity due to lopinavir/ritonavir.
The following characteristics of the paraplegic symptoms were
noted; First, a symmetric and rapid development. Secondly
DTRs was lost upon neurological examination. Third no pre-
disposing infection preceded, and fourth, the symptoms fully
disappeared in two months. According to these findings, the
most likely diagnosis is Guillain-Barre syndrome. Although
stavudine is suspected to be the likely cause of this Guilla-
in-Barre syndrome in view of the accompanying lactic acido-
sis; however, we could not confirm stavudine as the cause due
to the lack of a nerve conduction velocity test.
SUMMARY
NRTI, used in HAART, suppresses mitochondrial DNA poly-
merase-γ driven DNA synthesis;. Thus, it could possibly cause
serious adverse effects, such as lactic acidosis, hepatic steato-
sis and myopathy. Because we experienced this case of lactic
acidosis during the administration of stavudine in an AIDS pati-
ent, and this was followed by a subsequent successful treat-
ment, we report this case and include a review of the literature.
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